Topics

Global neoantigen cancer vaccine market to generate $1,826.1m revenue by 2030

07:51 EST 15 Jan 2020 | European Pharmaceutical Review

A study suggests the global neoantigen cancer vaccine market will grow exponentially due to expected drug launches, new technology reducing costs and currently unmet needs of the market.

The post Global neoantigen cancer vaccine market to generate $1,826.1m revenue by 2030 appeared first on European Pharmaceutical Review.

Original Article: Global neoantigen cancer vaccine market to generate $1,826.1m revenue by 2030

NEXT ARTICLE

More From BioPortfolio on "Global neoantigen cancer vaccine market to generate $1,826.1m revenue by 2030"

Quick Search

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...